STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp director Katryn Blake reported a sale of 2,240 shares of common stock on August 12, 2026 at $122.88 per share. According to the company’s disclosure, the shares were sold to cover tax liabilities arising from the vesting of Restricted Stock Units pursuant to a prior election and did not represent a discretionary trade. Following this transaction, Blake directly holds 17,208 shares of Twist Bioscience common stock.

Positive

  • None.

Negative

  • None.
Insider BLAKE KATRYN
Role Director
Sold 2,240 shs ($275K)
Type Security Shares Price Value
Sale Common Stock F1 2,240 $122.88 $275K
Holdings After Transaction: Common Stock — 17,208 shares (Direct)
Footnotes (1)
  1. F1. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.
Shares sold 2,240 shares Common stock sold on August 12, 2026 to cover tax liability
Sale price $122.88 per share Price for the 2,240 Twist Bioscience common shares sold
Shares held after transaction 17,208 shares Direct ownership by Katryn Blake after the tax-related sale
Net shares sold 2,240 shares Net sell direction reported in transaction summary
Restricted Stock Units financial
"tax liability in connection with the vesting of Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"This "sell to cover" transaction was made pursuant to a prior election"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
discretionary trade financial
"does not represent a discretionary trade by the Reporting Person"

FAQ

What insider transaction did Twist Bioscience (TWST) disclose for Katryn Blake?
Twist Bioscience disclosed that director Katryn Blake sold 2,240 shares of common stock on August 12, 2026 at $122.88 per share in a tax-related transaction tied to RSU vesting.

Was the TWST insider sale by Katryn Blake a discretionary trade?
No. The company states the 2,240-share sale was a “sell to cover” for tax liabilities from Restricted Stock Unit vesting, executed under a prior election and not as a discretionary trade.

How many Twist Bioscience (TWST) shares does Katryn Blake hold after the reported sale?
After the transaction, Katryn Blake directly holds 17,208 shares of Twist Bioscience common stock, according to the reported post-transaction ownership figure in the Form 4 filing.

Does the Katryn Blake Form 4 for Twist Bioscience (TWST) involve options or other derivatives?
No derivative transactions are listed. The filing reports only a non-derivative sale of 2,240 shares of common stock, related to tax withholding for vested Restricted Stock Units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BLAKE KATRYN
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/12/2026S2,240(1)D$122.8817,208D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Katryn Blake08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR